NIH-funded research R21 grant

Tracking Listeria bacteria in the body using advanced imaging techniques

Official title: Monitoring Listeria in vivo using 18FDG and PET scan

Funded at Albert Einstein College of Medicine · NIH-10946950 · Data updated 2026-11-12

This study is testing a new way to use Listeria bacteria to help your immune system fight advanced pancreatic cancer, and it will use special imaging to see how well the treatment works after it's injected.

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionAlbert Einstein College of Medicine
NIH-funded
Lab location1 site (Bronx, United States)
Project startJuly 15, 2024
Project endJune 30, 2026
Funding year2024
Award (this year)$431,970
NIH project number1R21CA292190-01
Project IDNIH-10946950 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are patients diagnosed with advanced pancreatic cancer who have previously received vaccinations that generated TT-specific memory T cells.

Less likely to help

Patients with early-stage pancreatic cancer or those who have not been vaccinated in childhood may not benefit from this research.

What this research studies

This research investigates a new method to deliver a cancer treatment using Listeria bacteria, which can attract the body's immune cells to attack tumors. By using a special imaging technique called PET scan with a glucose analogue, the researchers aim to visualize the presence of Listeria in the body after it is injected. This approach is particularly focused on patients with advanced pancreatic cancer, as it seeks to improve the targeting of the immune response to the tumors. The study will explore the effectiveness of intraperitoneal injections of Listeria, a method not previously tested in patients.

Why it matters

Potential benefit: If successful, this research could lead to a more effective treatment for advanced pancreatic cancer by harnessing the immune system to target tumors.

How similar studies have gone: While Listeria has been used in cancer treatments for years, this specific approach of intraperitoneal injection and monitoring with PET scans is novel and has not been previously tested in patients.

Where this research is happening

  • Albert Einstein College of Medicine
    Bronx, United States
    Active

Researchers

  • Principal investigator: Gravekamp, Claudia — Albert Einstein College of Medicine
  • Study coordinator: Gravekamp, Claudia

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.